Gradient of Risk and Associations with Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations from VERTIS CV.

1Division of Nephrology, University of Toronto, Toronto, Ontario, Canada; 2Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, TX; 3Department of Endocrinology and Diabetes, University of Nantes, Nantes, France; 4Unit of Cardiology, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden; 5Diabetes Institute, AdventHealth Translational Research Institute, Orlando, FL; 6Division of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis, TN; 7Research and Development, Pfizer Inc., Collegeville, PA; 8Diabetes and Endocrinology, MSD Limited, London, UK; 9Diabetes and Endocrinology, Merck & Co., Inc., Kenilworth, NJ; 10Biostatistics, Merck & Co., Inc., Kenilworth, NJ; 11Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA